Molecular Profile | KRAS G12D EZH2 pos |
Therapy | GSK343 + Selumetinib |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | no benefit |
Create By | spatt |
Update By | spatt |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | KRAS G12D EZH2 pos | lung adenocarcinoma | no benefit | GSK343 + Selumetinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of GSK343 did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756). | 26676756 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(26676756) | Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations. | Full reference... |